Nicholas R. Anthonisen
University of Manitoba
130 Papers
1.3K Citations
Nicholas R. Anthonisen is an academic researcher from University of Manitoba. The author has contributed to research in topics: COPD & Asthma. The author has an hindex of 52, co-authored 130 publications. Previous affiliations of Nicholas R. Anthonisen include St. Paul's Hospital & Harvard University.
Chat about Author
Papers
Antibiotic Therapy in Exacerbations of Chronic Obstructive Pulmonary Disease
Nicholas R. Anthonisen,Jure Manfreda,C. P. W. Warren,Earl Hershfield,G. K. M. Harding,N. A. Nelson +5 more
TL;DR: There was a significant benefit associated with antibiotic and Peak flow recovered more rapidly with antibiotic treatment than with placebo, and side effects were uncommon and did not differ between antibiotic and placebo.
2.5K
Azithromycin for Prevention of Exacerbations of COPD
Richard K. Albert,Richard K. Albert,John E. Connett,William C. Bailey,Richard Casaburi,J. Allen D. Cooper,Gerard J. Criner,Jeffrey L. Curtis,Mark T. Dransfield,MeiLan K. Han,Stephen C. Lazarus,Barry J. Make,Nathaniel Marchetti,Fernando J. Martinez,Nancy E. Madinger,Charlene McEvoy,Dennis E. Niewoehner,Janos Porsasz,Connie S. Price,Connie S. Price,John J. Reilly,Paul D. Scanlon,Frank C. Sciurba,Steven M. Scharf,George R. Washko,Prescott G. Woodruff,Nicholas R. Anthonisen +26 more
TL;DR: Among selected subjects with COPD, azithromycin taken daily for 1 year, when added to usual treatment, decreased the frequency of exacerbations and improved quality of life but caused hearing decrements in a small percentage of subjects.
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.
Nicholas R. Anthonisen,Melissa Skeans,Robert A. Wise,Jure Manfreda,Richard E. Kanner,John E. Connett +5 more
TL;DR: The smoking cessation program was associated with cumulative reduced decline in lung function (FEV1) that was largest in participants who stopped smoking early in the study; inhaled ipratropium produced a small noncumulative increase in FEV1 that disappeared when the drug was withdrawn.
1.1K
An Official American Thoracic Society Public Policy Statement: Novel Risk Factors and the Global Burden of Chronic Obstructive Pulmonary Disease
Mark D. Eisner,Nicholas R. Anthonisen,David B. Coultas,Nino Kuenzli,Rogelio Pérez-Padilla,Dirkje S. Postma,Isabelle Romieu,Edwin K. Silverman,John R. Balmes +8 more
TL;DR: It is concluded that specific genetic syndromes and occupational exposures were causally related to the development of COPD and a substantive burden of COPd is attributable to risk factors other than smoking.
Smoking and Lung Function of Lung Health Study Participants after 11 Years
TL;DR: Differences in lung function between treatment groups persisted; smoking intervention participants had less decline in FEV(1) than usual care participants and smoking habits by original LHS treatment groups tended to converge.
763